Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozagrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 known ✓ | P24557 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | USP2 | O75604 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozagrel SCHEMBL36183 | 1.00 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493930 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL27808192 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL10493936 | 0.99 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4210 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL4211 | 0.99 | TBXAS1 (1.00) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582828 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL582827 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL1652693 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 | |
| Ozagrel SCHEMBL28049244 | 0.97 | TBXAS1 (0.97) | TBXAS1CYP1A2USP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 937 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843529-B | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | Beijing Sunshine Nuohe Pharmaceutical Research Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-119818454-A | Ozagrel hydrochloride capsule and preparation method thereof | 杭州华东医药集团新药研究院有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118206580-A | Preparation method of ozagrel hydrochloride intermediate | 山东新时代药业有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-117843529-A | Resolution method of ozagrel hydrochloride intermediate and preparation method of ozagrel hydrochloride | 北京阳光诺和药物研究股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | claimed |
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | claimed |
| US-20170304388-A1 | NEW INDICATION OF CARDIOVASCULAR DRUGS FOR PREPARATION OF CANCER INHIBITION PHARMACEUTICAL COMPOSITION | LAUNX BIOMEDICAL CO., LTD. (TW) | 2017-10-26 | — | — | US | claimed |
| CN-102626388-B | Liposome solid preparation of ozagrel | HAINAN YONGTIAN DRUG RES INST CO LTD | 2013-05-29 | — | — | CN | claimed |
| CN-103006644-A | Method for preventing and treating thrombogenesis | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2013-04-03 | — | — | CN | claimed |
| EP-1010435-B1 | NANOCAPSULE PREPARATIONS FOR TREATING INTRAARTICULAR DISEASES | MARUHO K K (JP) | 2010-11-03 | — | — | EP | claimed |
| EP-1242068-A4 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED INC (US) | 2007-04-25 | — | — | EP | claimed |
| US-20030050305-A1 | Thromboxane inhibitors, compositions and methods of use | NITROMED, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1242068-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | Nitromed, Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001089519-A1 | THROMBOXANE INHIBITORS, COMPOSITIONS AND METHODS OF USE RELATED APPLICATIONS | NITROMED, INC. (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001032167-A1 | ENDOGENOUS NITRIC OXIDE SYNTHESIS UNDER CONDITIONS OF LOW OXYGEN TENSION | NITROMED, INC. (US) | 2001-05-10 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0058079-B1 | 4-(1-IMIDAZOLYLMETHYL)CINNAMIC ACID HYDROCHLORIDE MONOHYDRATE, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Kissei Pharmaceutical Co. Ltd. (JP) | 1985-01-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | TBXAS1 739/4885CYP1A2 45/4885USP2 4823/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | TBXAS1 739/4885CYP1A2 45/4885USP2 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.